Human papillomavirus screening and vaccines for cancer prevention: What is on the horizon?

Research output: Contribution to journalArticle

Abstract

This perspective aims to look at how the recently licensed human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), will impact cervical cancer globally, and what remains to be done in this field. The current VLP vaccines protect against infection from a substantial proportion, but not all, of the oncogenic HPV genotypes, and they have no proven therapeutic benefit for patients with HPV disease. Furthermore, they are too costly for sustained global use, and it is unclear how they may impact current cytologic screening protocols. A number of new technologies show promise in addressing these issues, including molecular screening tools and alternative vaccine strategies.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalTherapy
Volume5
Issue number3
DOIs
StatePublished - May 2008

Fingerprint

Papillomavirus Vaccines
Early Detection of Cancer
Virus-Like Particle Vaccines
Uterine Cervical Neoplasms
Virion
Vaccines
Genotype
Technology
Infection
Therapeutics

Keywords

  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • DNA vaccination
  • E6
  • E7
  • Human papillomavirus
  • L1 VLP
  • L2
  • Preventive vaccination
  • Therapeutic vaccination
  • Viral vectors

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Human papillomavirus screening and vaccines for cancer prevention : What is on the horizon? / Trimble, Cornelia L; Gravitt, Patti; Roden, Richard S.

In: Therapy, Vol. 5, No. 3, 05.2008, p. 295-303.

Research output: Contribution to journalArticle

@article{a232764b58b941e3ae2a0c0cb2040f0f,
title = "Human papillomavirus screening and vaccines for cancer prevention: What is on the horizon?",
abstract = "This perspective aims to look at how the recently licensed human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), will impact cervical cancer globally, and what remains to be done in this field. The current VLP vaccines protect against infection from a substantial proportion, but not all, of the oncogenic HPV genotypes, and they have no proven therapeutic benefit for patients with HPV disease. Furthermore, they are too costly for sustained global use, and it is unclear how they may impact current cytologic screening protocols. A number of new technologies show promise in addressing these issues, including molecular screening tools and alternative vaccine strategies.",
keywords = "Cervical cancer, Cervical intraepithelial neoplasia, DNA vaccination, E6, E7, Human papillomavirus, L1 VLP, L2, Preventive vaccination, Therapeutic vaccination, Viral vectors",
author = "Trimble, {Cornelia L} and Patti Gravitt and Roden, {Richard S}",
year = "2008",
month = "5",
doi = "10.2217/14750708.5.3.295",
language = "English (US)",
volume = "5",
pages = "295--303",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Human papillomavirus screening and vaccines for cancer prevention

T2 - What is on the horizon?

AU - Trimble, Cornelia L

AU - Gravitt, Patti

AU - Roden, Richard S

PY - 2008/5

Y1 - 2008/5

N2 - This perspective aims to look at how the recently licensed human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), will impact cervical cancer globally, and what remains to be done in this field. The current VLP vaccines protect against infection from a substantial proportion, but not all, of the oncogenic HPV genotypes, and they have no proven therapeutic benefit for patients with HPV disease. Furthermore, they are too costly for sustained global use, and it is unclear how they may impact current cytologic screening protocols. A number of new technologies show promise in addressing these issues, including molecular screening tools and alternative vaccine strategies.

AB - This perspective aims to look at how the recently licensed human papillomavirus (HPV) vaccines, based on L1 virus-like particles (VLPs), will impact cervical cancer globally, and what remains to be done in this field. The current VLP vaccines protect against infection from a substantial proportion, but not all, of the oncogenic HPV genotypes, and they have no proven therapeutic benefit for patients with HPV disease. Furthermore, they are too costly for sustained global use, and it is unclear how they may impact current cytologic screening protocols. A number of new technologies show promise in addressing these issues, including molecular screening tools and alternative vaccine strategies.

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - DNA vaccination

KW - E6

KW - E7

KW - Human papillomavirus

KW - L1 VLP

KW - L2

KW - Preventive vaccination

KW - Therapeutic vaccination

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=44649109136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649109136&partnerID=8YFLogxK

U2 - 10.2217/14750708.5.3.295

DO - 10.2217/14750708.5.3.295

M3 - Article

AN - SCOPUS:44649109136

VL - 5

SP - 295

EP - 303

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 3

ER -